Medtronic plc Dossier

Medtronic plc reported total revenue of $33.537 billion and operating income of $5.955 billion for the fiscal year ended April 25, 2025, with the Cardiovascular Portfolio contributing the largest portion of sales at $12.481 billion.

Financial Highlights

* Total Revenue: $33.537 billion

* Operating Income: $5.955 billion

* Non-GAAP Diluted EPS: $5.49

* GAAP Net Income: $4.662 billion

* Free Cash Flow: $5.185 billion

* Operating Cash Flow: $7.044 billion

* Research and Development Expense: $2.732 billion

* Dividends Paid: $3.589 billion

Medtronic plc operates as a diversified medical technology leader, structuring its commercial activities across four primary portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Under the leadership of CEO Geoff Martha, the company generated $12.481 billion from its Cardiovascular segment in fiscal year 2025, while the Neuroscience and Medical Surgical segments reported revenues of $9.846 billion and $8.407 billion, respectively. The Diabetes segment, which accounted for $2.755 billion in revenue, is currently the subject... Sign in / Sign up to learn more about Medtronic plc

Continue your research by chatting with our AI financial analyst about Medtronic plc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given that Medtronic plc's Diabetes segment achieved 10.7% revenue growth in FY2025, what is the strategic rationale for separating this business, and what are the potential impacts on the remaining company's growth trajectory and valuation?
• Medtronic plc's Medical Surgical segment saw a slight revenue contraction in FY2025. How does the company's investment in the Hugo™ robotic-assisted surgery system aim to reverse this trend, and what are the primary competitive and market adoption hurdles for this key growth initiative?
• Considering the ongoing litigation Medtronic plc faces regarding hernia mesh, insulin pumps, and tax disputes, what is the potential aggregate financial impact on the company's earnings and free cash flow, and how might these contingencies affect investor sentiment?
• In light of the recent report of an activist shareholder, how might Medtronic plc's long-standing capital allocation policy, including its 48-year record of dividend growth, be influenced, and what strategic adjustments could be considered to enhance shareholder value?
• Medtronic plc achieved a 34% reduction in product complaints during FY2025. How does this significant quality improvement strengthen its competitive moat, and what is its quantifiable impact on financial performance through factors like reduced operational costs and legal liabilities?